BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03914742 |
|
Recruitment Status :
Completed
First Posted : April 16, 2019
Last Update Posted : February 9, 2024
|
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
National Cancer Institute (NCI)
BeiGene
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | October 31, 2023 |
| Actual Study Completion Date : | October 31, 2023 |